Marsha Jones

The American Heart Association 2030 Impact Goal: A Presidential Advisory From the American Heart Association

Sonia Y. Angell, Michael V. McConnell, Cheryl A.M. Anderson et al. · Circulation · 2020 · 196 citations · Full text

Public Affairs, Cardiology, Health Policy +17

Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer

Ignace Vergote, N. Finkler, J. Del Campo et al. · European Journal of Cancer · 2009 · 102 citations

Medicine, Oncology, Pharmacology +16

Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome

Azra Raza, Naomi Galili, Natalie S. Callander et al. · Journal of Hematology & Oncology · 2009 · 66 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome

Azra Raza, Naomi Galili, Scott E. Smith et al. · Blood · 2009 · 65 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer

Ignace Vergote, Neil J. Finkler, James B. Hall et al. · International Journal of Gynecological Cancer · 2010 · 62 citations

Medicine, Oncology, Pharmacology +16